CORESTEMCHEMON INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11,330 KRW | -10.79% |
|
+16.44% | +67.36% |
| Sales 2022 | 46.29B 33.7M | Sales 2023 | 33.66B 24.5M | Capitalization | 145B 106M |
|---|---|---|---|---|---|
| Net income 2022 | -2.66B -1.93M | Net income 2023 | -17.67B -12.87M | EV / Sales 2022 | 5.86 x |
| Net Debt 2022 | 15.84B 11.53M | Net Debt 2023 | 30.06B 21.89M | EV / Sales 2023 | 5.2 x |
| P/E ratio 2022 |
-14
x | P/E ratio 2023 |
-8.09
x | Employees | 376 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 53.1% |
More Fundamentals
* Assessed data
More news
| 1 day | -10.79% | ||
| 1 week | +16.44% | ||
| Current month | +5.00% | ||
| 1 month | +6.89% | ||
| 3 months | +46.19% | ||
| 6 months | +102.32% | ||
| Current year | +67.36% |
1 week
9 750.00
13 440.00
1 month
9 600.0013 440.00
Current year
6 490.0013 440.00
1 year
5 250.0013 440.00
3 years
5 250.0024 800.00
5 years
5 250.0034 350.00
10 years
5 250.0048 500.00
| Managers | Title | Age | Since |
|---|---|---|---|
Gyeong-Sook Kim
CEO | Chief Executive Officer | 59 | - |
Tae-Yong Lee
CTO | Chief Tech/Sci/R&D Officer | 42 | - |
Heon-Jeong Lim
AUD | Comptroller/Controller/Auditor | 56 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gyeong-Sook Kim
CEO | Chief Executive Officer | 59 | - |
Kwan-Hee Hong
BRD | Director/Board Member | 65 | 18-02-28 |
Sang-Bae Han
BRD | Director/Board Member | 59 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 11,330 | -10.79% | 761 041 |
| 24-04-18 | 12,700 | +3.25% | 932,481 |
| 24-04-17 | 12,300 | +11.92% | 1,300,122 |
| 24-04-16 | 10,990 | +10.67% | 769,945 |
| 24-04-15 | 9,930 | +0.10% | 86,681 |
End-of-day quote Korea S.E., April 18, 2024
More quotes
Corestemchemon Inc, formerly Corestem Inc, is a Korea-based company engaged in the development, production and sale of stem cell therapies for intractable diseases. The Company operates its business through two segments. The Non-clinical Contract Research Organization (CRO) Business segment is engaged in the provision of research and development services such as toxicity (safety) verification and drug efficacy (efficacy) verification in the non-clinical stage. The Cell Therapy Business segment is engaged in the development, production and sale of Lou Gehrig's disease treatments such as Neuronata-R.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +67.36% | 198M | |
| -1.42% | 41.35B | |
| +42.15% | 40.38B | |
| +1.97% | 39.05B | |
| -14.19% | 26.67B | |
| +1.82% | 24.07B | |
| -24.55% | 18.36B | |
| -4.07% | 11.68B | |
| +21.36% | 11.6B | |
| +8.20% | 11.15B |
- Stock Market
- Equities
- A166480 Stock
